<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319712437031</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319712437031</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Peripheral Arterial Disease</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Reduced Plasma Eicosapentaenoic Acid–Arachidonic Acid Ratio in Peripheral Artery Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Fujihara</surname>
<given-names>Masahiko</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712437031">1</xref>
<xref ref-type="aff" rid="aff2-0003319712437031">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fukata</surname>
<given-names>Mitsuhiro</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712437031">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Odashiro</surname>
<given-names>Keita</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712437031">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Maruyama</surname>
<given-names>Toru</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff3-0003319712437031">3</xref>
<xref ref-type="corresp" rid="corresp1-0003319712437031"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Akashi</surname>
<given-names>Koichi</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712437031">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yokoi</surname>
<given-names>Yoshiaki</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0003319712437031">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319712437031"><label>1</label>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan</aff>
<aff id="aff2-0003319712437031"><label>2</label>Department of Cardiology, Kishiwada Tokushukai Hospital, Osaka, Japan</aff>
<aff id="aff3-0003319712437031"><label>3</label>Institute of Health Science, Kyushu University, Kasuga, Japan</aff>
<author-notes>
<corresp id="corresp1-0003319712437031">Toru Maruyama, Institute of Health Science, Kyushu University, Kasuga Kohen 6-1, Kasuga 816-8580, Japan Email: <email>maruyama@ihs.kyushu-u.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>64</volume>
<issue>2</issue>
<fpage>112</fpage>
<lpage>118</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>A reduced ratio of plasma eicosapentaenoic acid–arachidonic acid (EPA-AA) is a newly recognized atherosclerotic risk factor. This ratio has not been fully investigated in peripheral artery disease (PAD). Seventy Japanese patients with atherosclerotic risk factors were enrolled and divided into 2 groups, those with PAD (group A: n = 38) and those without PAD (group B: n = 32). The EPA-AA ratio (<italic>P</italic> = .001) and ankle–brachial index (ABI: <italic>P</italic> &lt; .001) in group A were significantly lower than those in group B. Univariate and multivariate analyses demonstrated that EPA-AA, ABI, and prescription of clopidogrel had significant correlation with PAD. Given the appropriate cutoff values, EPA-AA (odds ratio [OR] = 11.7, 95% confidence interval [CI] = 3.0-45.8; <italic>P</italic> &lt; .001) and ABI (OR = 44.0, 95% CI = 5.4-358.5; <italic>P </italic>&lt; .001) are factors independently associated with PAD. In conclusion, this study demonstrated that reduced plasma EPA/AA may underlie PAD at least in Japanese.</p>
</abstract>
<kwd-group>
<kwd>ankle–brachial index</kwd>
<kwd>atherosclerosis</kwd>
<kwd>eicosapentaenoic acid</kwd>
<kwd>arachidonic acid</kwd>
<kwd>peripheral artery disease</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319712437031">
<title>Introduction</title>
<p>Peripheral artery disease (PAD) is one of the major atherosclerotic manifestations, showing progressive lipid, inflammatory cell, and fibrous matter accumulation in peripheral arteries in the lower extremities. Peripheral artery disease impairs not only the quality of life but also the long-term prognosis of patients with atherosclerosis due to the coexisting coronary artery disease (CAD), which is a major cause of mortality and morbidity in patients with PAD.</p>
<p>Reportedly, relative risk of dying in patients with PAD compared with that in controls is 3.1 for deaths from all causes, 5.9 for all cardiovascular deaths, and 6.6 for deaths from CAD.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712437031">1</xref>
</sup> An increasing body of evidence indicates that dietary intake of fish-derived polyunsaturated fatty acid shows favorable outcome in patients with CAD,<sup>
<xref ref-type="bibr" rid="bibr2-0003319712437031">2</xref>,<xref ref-type="bibr" rid="bibr3-0003319712437031">3</xref>
</sup>since plasma essential fatty acids and their profile exert protective effects against atherosclerotic progression. The Japan eicosapentaenoic acid (EPA) lipid intervention study (JELIS) showed for the first time that additive administration of purified EPA reduced coronary events by 19% in patients undergoing statin prescription.<sup>
<xref ref-type="bibr" rid="bibr4-0003319712437031">4</xref>
</sup> Moreover, subanalyses of JELIS demonstrated that EPA reduced the incidence of recurrent stroke<sup>
<xref ref-type="bibr" rid="bibr5-0003319712437031">5</xref>
</sup> and of CAD in patients complicated with PAD.<sup>
<xref ref-type="bibr" rid="bibr6-0003319712437031">6</xref>
</sup>
</p>
<p>Dietary essential fatty acids are classified into n-3 (eg, EPA) and n-6 (eg, arachidonic acid [AA]) groups, and the metabolites of these fatty acids have mutually opposing effects on CAD. Therefore, the balance of plasma n-3 and n-6 fatty acids is linked to the progression of CAD.<sup>
<xref ref-type="bibr" rid="bibr7-0003319712437031">7</xref>
</sup> The plasma EPA-AA ratio is an atherosclerotic biomarker reflecting the intrinsic n-3/n-6 ratio. However, clinical studies investigating the association of plasma EPA-AA ratio with the incidence of PAD are limited.<sup>
<xref ref-type="bibr" rid="bibr8-0003319712437031">8</xref>
</sup>
</p>
<p>According to the JELIS trials,<sup>
<xref ref-type="bibr" rid="bibr4-0003319712437031">4</xref>
<xref ref-type="bibr" rid="bibr5-0003319712437031"/>–<xref ref-type="bibr" rid="bibr6-0003319712437031">6</xref>
</sup> we hypothesized that among other conventional atherosclerotic risk factors, the intrinsic plasma EPA-AA ratio plays a key role in the development of PAD that requires endovascular therapy. Therefore, the present study was designed to test this hypothesis.</p>
</sec>
<sec id="section2-0003319712437031" sec-type="methods">
<title>Patients and Methods</title>
<sec id="section3-0003319712437031">
<title>Participants</title>
<p>This study was approved by the Institutional Review Board concerning Ethics of Clinical Research and performed from March to September 2010, according to the Declaration of Helsinki (2001). Japanese patients who were referred to Kyushu University Hospital for thorough examinations of suspected atherosclerosis were consecutively nominated in this study. Among 81 hospitalized patients, 70 consecutive patients without the prescription for purified EPA (1800 mg/d) were finally enrolled. Informed consent was obtained from each patient after admission for acquisition of data concerning plasma EPA-AA ratio.</p>
<p>Ankle–brachial index (ABI) was evaluated routinely in our vascular laboratory (ABI Form, Omron-Colin, Tokyo, Japan) for all the hospitalized patients. ABI was assessed utilizing both the anterior and the posterior tibial arteries.<sup>
<xref ref-type="bibr" rid="bibr9-0003319712437031">9</xref>
</sup> Additionally, 2 kinds of duplex ultrasonography (Xario, Toshiba Medical Systems, Otawara, Japan; iE33, Philips Electronics Japan, Tokyo, Japan) were applied routinely to bilateral carotid, renal, and peripheral arteries in lower extremities. When ultrasonography showed positive findings, a further imaging protocol was added for endovascular therapeutic strategies, that is, contrast-enhanced multidetector computed tomography (Aquilion TSX-101A, Toshiba Medical Systems) and 2 different superconductive magnetic resonance imaging units (Signa, General Electric Medical Systems, Milwaukee, Wisconsin; Magnetom Vision &amp; Symphony Units, Siemens, Erlangen, Germany) were involved.</p>
<p>These patients showing atherosclerotic risk factors were divided into 2 groups, those with PAD (group A: n = 38) and those without PAD (group B: n = 32). Group A included patients with CAD (n = 20), carotid artery stenosis (n = 3), and renal artery stenosis (n = 6), whereas group B included CAD (n = 23). Endovascular therapy for PAD was successful in all the patients in group A.</p>
</sec>
<sec id="section4-0003319712437031">
<title>Protocol</title>
<p>Baseline characteristics and drug prescriptions were investigated using medical records. Demographic variables, conventional atherosclerotic risk factors, plasma EPA-AA ratio, and prescription were analyzed in the 2 groups. Data collection and analyses were performed blindly by different physicians. Hypertension was defined as casual blood pressure <underline>≥</underline>149/90 mm Hg and/or ongoing antihypertensive treatment.<sup>
<xref ref-type="bibr" rid="bibr10-0003319712437031">10</xref>
</sup> Diabetes was defined as HbA<sub>1c</sub> <underline>≥</underline>6.5% and/or antidiabetic medication. Dyslipidemia was also defined as serum low-density lipoprotein (LDL) cholesterol <underline>≥</underline>140 mg/dL, serum high-density lipoprotein (HDL) cholesterol &lt;40 mg/dL or the prescription of lipid-lowering agents.<sup>
<xref ref-type="bibr" rid="bibr11-0003319712437031">11</xref>
</sup> Medication included antiplatelet agents (aspirin, clopidogrel, cilostazol, and ticlopidine) for atherosclerosis, statins for dyslipidemia, antihypertensive agents (calcium antagonists, α-blockers, β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) for hypertension, and hypoglycemic agents (sulfonylurea, metformin, and α-glucosidase inhibitors) for type 2 diabetes. Prescription was not altered in any patient during the study.</p>
</sec>
<sec id="section5-0003319712437031">
<title>Data Analysis</title>
<p>Continuous data are expressed as means ± standard deviation, and categorical data are expressed as numbers (n) and percentage in parentheses. For continuous data, the normality of the distribution was examined by the Kolmogorov-Smirnov test. Intergroup comparison of continuous data was made by Student <italic>t</italic> test for normally distributed data, and by Mann-Whitney <italic>U</italic> test for other data. Comparison of continuous data among more than 2 groups was performed by analysis of variance (ANOVA) for normally distributed data, and by Kruskal-Wallis test for other data. Categorical data were analyzed by Fisher exact test or Pearson χ<sup>
<xref ref-type="bibr" rid="bibr2-0003319712437031">2</xref>
</sup> test with Yates continuity correction, if necessary. The assumptions used for power calculations required a sample size of more than 20 patients per group without any dropout cases to provide 80% power to detect a 5.0% difference in plasma EPA-AA ratio, with a 5% type I error rate for a 2-sided test. Univariate analysis was conducted by Spearman rank correlation test. Baseline characteristics showing significant difference in univariate analysis were incorporated into multivariate analysis. Receiver–operating characteristic (ROC) curves providing cutoff values of EPA-AA and ABI were constructed. Practical computation was performed using Predictive Analytics Software (PASW) 18.0 version for Windows (SPSS, Inc., IBM, Chicago, Illinois). A 2-sided <italic>P</italic> &lt; .050 was considered significant.</p>
</sec>
</sec>
<sec id="section6-0003319712437031">
<title>Results</title>
<p>Kolmogorov-Smirnov test demonstrated that distributions of plasma endogenous EPA-AA ratio (<italic>P</italic> = .007), ABI (<italic>P</italic> &lt; .001), and serum high-sensitivity C-reactive protein (hsCRP; <italic>P</italic> &lt; .001) were not normal. <xref ref-type="table" rid="table1-0003319712437031">Table 1</xref> shows comparisons of the demographic variables, distribution of atherosclerotic risk factors, laboratory data, and prescriptions between groups A and B. There were no differences in the incidence of hypertension, hyperuricemia, type 2 diabetes, dyslipidemia, CAD, and thoracoabdominal aortic aneurysm. Incidence of current smoking was equivalent. In laboratory investigations, plasma EPA concentration (<italic>P</italic> = .008), EPA-AA ratio (<italic>P</italic> = .001), and ABI (<italic>P</italic> &lt; .001) in group A were significantly lower than those in group B, whereas the difference in plasma AA concentration between the 2 groups was marginal (<italic>P</italic> = .050), indicating that the significantly lower plasma EPA-AA ratio in group A is due mainly to the lower EPA concentration. On the other hand, hsCRP showed no significant intergroup difference (<italic>P</italic> = .813). Distribution and difference of plasma EPA-AA ratio are detailed in <xref ref-type="fig" rid="fig1-0003319712437031">Figure 1</xref>. With respect to medication, prescriptions of clopidogrel (<italic>P</italic> = .038) and hypoglycemic agents (<italic>P</italic> = .032) in group A were significantly more frequent than those in group B.</p>
<fig id="fig1-0003319712437031" position="float">
<label>Figure 1.</label>
<caption>
<p>Distribution of the ratio of plasma eicosapentaenoic acid and arachidonic acid (EPA-AA). The EPA-AA ratio in group A (n = 38) was significantly (<italic>P</italic> = .001) lower than that in group B (n = 32).</p>
</caption>
<graphic xlink:href="10.1177_0003319712437031-fig1.tif"/>
</fig>
<table-wrap id="table1-0003319712437031" position="float">
<label>Table 1.</label>
<caption>
<p>Comparisons of Demographic Variables Between Group A and Group B<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table1-0003319712437031" xlink:href="10.1177_0003319712437031-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Group A</th>
<th>Group B</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>38</td>
<td>32</td>
<td>
</td>
</tr>
<tr>
<td>Age, years</td>
<td>69.8 ± 6.6</td>
<td>69.6 ± 9.2</td>
<td>.909 </td>
</tr>
<tr>
<td>Sex, F/M</td>
<td>11/27</td>
<td>6/26</td>
<td>.322 </td>
</tr>
<tr>
<td>BMI, kg/m<sup>2</sup>
</td>
<td>23.9 ± 3.4</td>
<td>24.3 ± 3.9</td>
<td>.607 </td>
</tr>
<tr>
<td>Current Smoking, %</td>
<td>76.3</td>
<td>71.9</td>
<td>.672 </td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>89.5 </td>
<td>93.8 </td>
<td>.524 </td>
</tr>
<tr>
<td>Diabetes mellitus, %</td>
<td>68.4</td>
<td>46.9</td>
<td>.068 </td>
</tr>
<tr>
<td> HbA<sub>1c</sub>, %</td>
<td>6.5 ± 1.0</td>
<td>6.2 ± 1.3</td>
<td>.433 </td>
</tr>
<tr>
<td>Dyslipidemia, %</td>
<td>76.3</td>
<td>84.4</td>
<td>.401 </td>
</tr>
<tr>
<td> TC, md/dL</td>
<td>178 ± 37</td>
<td>173 ± 35</td>
<td>.554 </td>
</tr>
<tr>
<td> LDL-C, mg/dL</td>
<td>102 ± 29</td>
<td>97 ± 32</td>
<td>.495 </td>
</tr>
<tr>
<td> HDL-C, mg/dL</td>
<td>47 ± 9</td>
<td>47 ± 12</td>
<td>.921 </td>
</tr>
<tr>
<td> TG, mg/dL</td>
<td>148 ± 61.5</td>
<td>132 ± 70</td>
<td>.205 </td>
</tr>
<tr>
<td>EPA, mg/dL</td>
<td>54.3 ± 25.3</td>
<td>69.7 ± 27.0</td>
<td>.008</td>
</tr>
<tr>
<td>AA, mg/dL</td>
<td>164.4 ± 40.2</td>
<td>146.6 ± 31.7</td>
<td>.050</td>
</tr>
<tr>
<td>EPA-AA ratio</td>
<td>0.33 ± 0.13</td>
<td>0.50 ± 0.22</td>
<td>.001</td>
</tr>
<tr>
<td>Hyperuricemia, %</td>
<td>31.6</td>
<td>21.9</td>
<td>.363 </td>
</tr>
<tr>
<td>Uric acid, mg/dL</td>
<td>5.9 ± 1.6</td>
<td>6.2 ± 1.3</td>
<td>.400 </td>
</tr>
<tr>
<td>hsCRP, mg/dL</td>
<td>0.54 ± 0.96</td>
<td>0.19 ± 0.25</td>
<td>.813</td>
</tr>
<tr>
<td>Serum Cr, mg/dL</td>
<td>1.38 ± 1.43</td>
<td>1.19 ± 1.31</td>
<td>.641</td>
</tr>
<tr>
<td>eGFR, mL/min/1.73 m<sup>2</sup>
</td>
<td>59 ± 23</td>
<td>61 ± 19</td>
<td>.513</td>
</tr>
<tr>
<td>ABI</td>
<td>0.84 ± 0.26</td>
<td>1.11 ± 0.10</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>CAD, %</td>
<td>52.6</td>
<td>71.9</td>
<td>.099 </td>
</tr>
<tr>
<td>TAA-AAA, %</td>
<td>21.1</td>
<td>37.5</td>
<td>.129 </td>
</tr>
<tr>
<td colspan="4">Medication, %</td>
</tr>
<tr>
<td>Aspirin</td>
<td>86.8</td>
<td>81.3</td>
<td>.522 </td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>52.6</td>
<td>28.1</td>
<td>.038</td>
</tr>
<tr>
<td>Ticlopidine</td>
<td>15.8</td>
<td>18.8</td>
<td>.743 </td>
</tr>
<tr>
<td>Warfarin</td>
<td>5.3</td>
<td>6.3</td>
<td>.859 </td>
</tr>
<tr>
<td>Cilostazol</td>
<td>15.8</td>
<td>3.1</td>
<td>.078 </td>
</tr>
<tr>
<td>Statin</td>
<td>84.2</td>
<td>78.1</td>
<td>.514 </td>
</tr>
<tr>
<td>Calcium blockers</td>
<td>47.4</td>
<td>53.1</td>
<td>.631</td>
</tr>
<tr>
<td>RAS inhibitors</td>
<td>60.5</td>
<td>68.8</td>
<td>.474 </td>
</tr>
<tr>
<td>Hypoglycemic agents</td>
<td>50.0</td>
<td>25.0</td>
<td>.032</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319712437031">
<p>
<sup>a</sup> Data are presented as percentage or mean ± standard deviation.</p>
</fn>
<fn id="table-fn2-0003319712437031">
<p>Abbreviations: AA, arachidonic acid; AAA, abdominal aortic aneurysm; ABI, ankle–brachial index; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; EPA, eicosapentaenoic acid; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; RAS, renin–angiotensin system; TAA, thoracic aortic aneurysm; TC, total cholesterol; TG, triglyceride.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>
<xref ref-type="table" rid="table2-0003319712437031">Table 2</xref> shows the results of univariate and multivariate analyses concerning PAD. In the univariate analysis, variables showing significance in <xref ref-type="table" rid="table1-0003319712437031">Table 1</xref> were investigated. As an essential fatty acid profile, EPA-AA ratio but not absolute plasma EPA concentration was adopted. Consequently, all variables revealed significant contribution to PAD. In multivariate analysis, plasma EPA-AA ratio (<italic>P</italic> = .018), ABI (<italic>P</italic> = .001), and prescription of clopidogrel (<italic>P</italic> = .014) remained as independent factors related to the presence of PAD. The relationship between plasma EPA-AA ratio and ABI was further examined (<xref ref-type="fig" rid="fig2-0003319712437031">Figure 2</xref>). Linear regression of ABI (<italic>y</italic>) as a function of EPA-AA (<italic>x</italic>) was significant ( <italic>y</italic> = 0.366<italic>x</italic> + 0.812, <italic>r</italic>
<sup>
<xref ref-type="bibr" rid="bibr2-0003319712437031">2</xref>
</sup> = .089; <italic>P</italic> = .013).</p>
<fig id="fig2-0003319712437031" position="float">
<label>Figure 2.</label>
<caption>
<p>Relationship between plasma EPA-AA ratio and ankle–brachial index (ABI). ABI (<italic>y</italic>) is shown as a function of EPA-AA (<italic>x</italic>), yielding a linear regression of <italic>y</italic> = 0.366<italic>x</italic> + 0.812 (<italic>r</italic>
<sup><xref ref-type="bibr" rid="bibr2-0003319712437031">2</xref></sup> = .089, <italic>P</italic> = .013). EPA indicates eicosapentaenoic acid; AA, arachidonic acid; ABI, ankle–brachial index.</p>
</caption>
<graphic xlink:href="10.1177_0003319712437031-fig2.tif"/>
</fig>
<table-wrap id="table2-0003319712437031" position="float">
<label>Table 2.</label>
<caption>
<p>Univariate and Multivariate Analyses of Demographic Variables in PAD</p>
</caption>
<graphic alternate-form-of="table2-0003319712437031" xlink:href="10.1177_0003319712437031-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Variables</th>
<th colspan="2">Univariate</th>
<th colspan="2">Multivariate</th>
</tr>
<tr>
<th>
<italic>R</italic>
</th>
<th>
<italic>P</italic>
</th>
<th>β</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPA-AA</td>
<td>−.427 </td>
<td>&lt;.001</td>
<td>−5.053</td>
<td>.018</td>
</tr>
<tr>
<td>ABI</td>
<td>−.548 </td>
<td>&lt;.001</td>
<td>−8.615</td>
<td>.001</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>.251 </td>
<td>.039 </td>
<td>−1.902</td>
<td>.014</td>
</tr>
<tr>
<td>Hypoglycemic agents</td>
<td>.256 </td>
<td>.033 </td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0003319712437031">
<p>Abbreviations: AA, arachidonic acid; ABI, ankle–brachial index; EPA, eicosapentaenoic acid; PAD, peripheral artery disease.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Analysis of ROC curves was performed to obtain the optimal cutoff values of plasma EPA-AA ratio and ABI for diagnosing PAD (<xref ref-type="fig" rid="fig3-0003319712437031">Figure 3</xref>). The areas under the curve for plasma EPA-AA ratio and for ABI were 0.734 and 0.824, respectively. It is of note that ABI shows high specificity under a wide range of sensitivity. Optimal cutoff value of the EPA-AA ratio was 0.43 and that of ABI was 0.90 as addressed by meta-analysis.<sup>
<xref ref-type="bibr" rid="bibr12-0003319712437031">12</xref>
</sup> Considering the high specificity of ABI, the cutoff value of the plasma EPA-AA ratio was set at 0.49 to improve its own sensitivity, whereas that of ABI was set at the optimal level (0.90). <xref ref-type="table" rid="table3-0003319712437031">Table 3</xref> shows the sensitivities and specificities of these 2 variables for the diagnosis of PAD under these cutoff values. It is of note that these 2 variables showed a sharp contrast, that is, sensitivity of EPA-AA was superior to that of ABI, while specificity of ABI was superior to that of EPA-AA, as in the literature.<sup>
<xref ref-type="bibr" rid="bibr12-0003319712437031">12</xref>
</sup> Under these cutoff values, diagnoses of PAD by plasma EPA-AA ratio (odds ratio [OR] = 11.7, 95% confidence interval [CI] = 3.0-45.8; <italic>P</italic> &lt; .001) and by ABI (OR = 44.0, 95% CI = 5.4-358.5; <italic>P</italic> &lt; .001) were highly significant.</p>
<fig id="fig3-0003319712437031" position="float">
<label>Figure 3.</label>
<caption>
<p>Receiver–operating characteristic curves for diagnosis of PAD by plasma EPA-AA ratio (A) and ABI (B). Area under the curve for EPA-AA is 0.734, and that for ABI is 0.824. EPA indicates eicosapentaenoic acid; AA, arachidonic acid; ABI, ankle–brachial index; PAD, peripheral artery disease.</p>
</caption>
<graphic xlink:href="10.1177_0003319712437031-fig3.tif"/>
</fig>
<table-wrap id="table3-0003319712437031" position="float">
<label>Table 3.</label>
<caption>
<p>Comparison of Plasma EPA-AA Ratio and ABI in PAD</p>
</caption>
<graphic alternate-form-of="table3-0003319712437031" xlink:href="10.1177_0003319712437031-table3.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>
</th>
<th colspan="3">PAD</th>
<th rowspan="2">Sensitivity (%)</th>
<th rowspan="2">Specificity (%)</th>
<th rowspan="2">OR</th>
<th rowspan="2">95% CI</th>
</tr>
<tr>
<th>
</th>
<th>
</th>
<th>(+)</th>
<th>(−)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="3">EPA-AA</td>
<td>&lt;0.49</td>
<td>35</td>
<td>16</td>
<td>51</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>≥0.49</td>
<td>3</td>
<td>16</td>
<td>19</td>
<td>92.1</td>
<td>50.0 </td>
<td>11.7 </td>
<td>3.0-45.8</td>
</tr>
<tr>
<td align="center">Total</td>
<td>38</td>
<td>32</td>
<td>70</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td rowspan="3">ABI</td>
<td>&lt;0.90</td>
<td>22</td>
<td>1</td>
<td>23</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>≥0.90</td>
<td>15</td>
<td>30</td>
<td>45</td>
<td>59.5</td>
<td>96.8 </td>
<td>44.0 </td>
<td>5.4-358.5</td>
</tr>
<tr>
<td align="center">Total</td>
<td>37</td>
<td>31</td>
<td>68</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0003319712437031">
<p>Abbreviations: AA, arachidonic acid; ABI, ankle–brachial index; CI, confidence interval; EPA, eicosapentaenoic acid; OD, odds ratio; PAD, peripheral artery disease.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Plasma essential fatty acid profile is known as a common risk factor for PAD and CAD in the Edinburgh Artery Study.<sup>
<xref ref-type="bibr" rid="bibr8-0003319712437031">8</xref>,<xref ref-type="bibr" rid="bibr13-0003319712437031">13</xref>
</sup> In order to compare the diagnostic significance of EPA-AA ratio in PAD with that in CAD, these patients were subdivided as follows: patients with CAD and PAD (group A1: n = 20), those with PAD and without CAD (group A2: n = 18), those with CAD and without PAD (group B1: n = 23), and those with neither CAD nor PAD (group B2: n =9). Plasma essential fatty acid profile was compared among the 4 subgroups (<xref ref-type="table" rid="table4-0003319712437031">Table 4</xref>). There were significant differences in plasma EPA concentration (<italic>P</italic> = .032) and EPA-AA ratio (<italic>P</italic> = .002) among the subgroups. Furthermore, given the same cutoff value as in PAD (0.49), sensitivity and specificity of this ratio concerning CAD were 74.1% and 23.3%, respectively. Sensitivity of this ratio for CAD tended to be lower (<italic>P</italic> = .052) than that for PAD, and specificity for CAD was significantly (<italic>P</italic> = .016) lower than that for PAD.</p>
<table-wrap id="table4-0003319712437031" position="float">
<label>Table 4.</label>
<caption>
<p>Comparisons of Essential Fatty Acid Profile in 4 Subgroups<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table4-0003319712437031" xlink:href="10.1177_0003319712437031-table4.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th colspan="2">A</th>
<th colspan="2">B</th>
</tr>
<tr>
<th>Subgroup</th>
<th>A1</th>
<th>A2</th>
<th>B1</th>
<th>B2</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAD</td>
<td align="center">(+)</td>
<td align="center">(+)</td>
<td>(−)</td>
<td align="center">(−)</td>
<td>
</td>
</tr>
<tr>
<td>CAD</td>
<td align="center">(+)</td>
<td align="center">(−)</td>
<td>(+)</td>
<td align="center">(−)</td>
<td>
</td>
</tr>
<tr>
<td>n</td>
<td align="center">20</td>
<td align="center">18</td>
<td>23</td>
<td align="center">9</td>
<td>
</td>
</tr>
<tr>
<td>EPA, μg/mL</td>
<td>47.9 ± 18.7</td>
<td>62.4 ± 29.7</td>
<td>67.7 ± 27.4</td>
<td>74.8 ± 26.6</td>
<td>.032</td>
</tr>
<tr>
<td>AA, μg/mL</td>
<td>161.1 ± 44.2</td>
<td>168.1 ± 36.0</td>
<td>145.7 ± 35.0</td>
<td>148.7 ± 22.9</td>
<td>.229</td>
</tr>
<tr>
<td>EPA-AA</td>
<td>0.30 ± 0.11</td>
<td>0.37 ± 0.14</td>
<td>0.50 ± 0.25</td>
<td>0.51 ± 0.17</td>
<td>.002</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0003319712437031">
<p>Abbreviations: AA, arachidonic acid; CAD, coronary artery disease; EPA, eicosapentaenoic acid; PAD, peripheral artery disease.</p>
</fn>
<fn id="table-fn6-0003319712437031">
<p>
<sup>a</sup> Data are presented as number of patients or mean ± standard deviation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section7-0003319712437031">
<title>Discussion</title>
<p>In the present study, plasma endogenous EPA-AA ratio and conventional atherosclerotic risk factors were analyzed in 70 consecutive Japanese patients with (group A) or without (group B) PAD. This study showed that EPA-AA and ABI in group A were significantly lower than those in group B (<xref ref-type="table" rid="table1-0003319712437031">Table 1</xref>) and were independently associated with PAD by multivariate analyses (<xref ref-type="table" rid="table2-0003319712437031">Table 2</xref>). The EPA-AA (OR = 11.7, 95% CI = 3.0-45.8, <italic>P</italic> &lt; .001) showed high sensitivity, and ABI (OR = 44.0, 95%CI = 5.4 – 358.5, <italic>P</italic> &lt; .001) showed high specificity (<xref ref-type="table" rid="table3-0003319712437031">Table 3</xref>). Because of the linear regression between EPA-AA and ABI (<xref ref-type="fig" rid="fig2-0003319712437031">Figure 2</xref>), reduced plasma EPA-AA ratio may indicate an etiological insight into PAD.</p>
<p>A series of JELIS trials conducted in Japanese atherosclerotic patients demonstrated that adjunctive prescription of EPA (C20: 5n-3) reduced the incidence of major coronary events,<sup>
<xref ref-type="bibr" rid="bibr4-0003319712437031">4</xref>
</sup> recurrent stroke,<sup>
<xref ref-type="bibr" rid="bibr5-0003319712437031">5</xref>
</sup> and CAD in patients complicated with PAD.<sup>
<xref ref-type="bibr" rid="bibr6-0003319712437031">6</xref>
</sup> However, there is limited data concerning direct relationship between essential fatty acid and PAD. In Western countries, Edinburgh Artery Study did not clarify the cross-sectional relationship of plasma EPA and the incidence of PAD by a population-based approach.<sup>
<xref ref-type="bibr" rid="bibr8-0003319712437031">8</xref>
</sup> In contrast, strong association of plasma EPA-AA ratio with PAD was obtained by this study (<xref ref-type="table" rid="table2-0003319712437031">Tables 2</xref> and <xref ref-type="table" rid="table3-0003319712437031">3</xref>). This discrepancy seems to be attributable to the different ethnicity and study design. This is a case–control study using Japanese atherosclerotic patients. Ethnic difference in essential fatty acid profile depends greatly on fish consumption.<sup>
<xref ref-type="bibr" rid="bibr14-0003319712437031">14</xref>
</sup> Baseline EPA-AA ratio in Japanese is greater than that in Westerners,<sup>
<xref ref-type="bibr" rid="bibr15-0003319712437031">15</xref>
</sup> which makes international comparison of domestic lipid investigations difficult. The Edinburgh Artery Study demonstrated that n-3 fatty acids, especially docosapentaenoic acid (C22: 5n-3),<sup>
<xref ref-type="bibr" rid="bibr16-0003319712437031">16</xref>
</sup>exert protective effects against PAD.<sup>
<xref ref-type="bibr" rid="bibr8-0003319712437031">8</xref>
</sup> Although diagnosis of PAD in a population approach is limited to history taking and ABI estimation,<sup>
<xref ref-type="bibr" rid="bibr17-0003319712437031">17</xref>
</sup> their findings are compatible with those of this study, that is, the essential fatty acid profile remained as an independent factor related to PAD (<xref ref-type="table" rid="table2-0003319712437031">Table 2</xref>).</p>
<p>Atherosclerotic prevention by additive administration of purified EPA is evident.<sup>
<xref ref-type="bibr" rid="bibr4-0003319712437031">4</xref>,<xref ref-type="bibr" rid="bibr6-0003319712437031">6</xref>
</sup> Metabolites of AA (C20: 4n-6), such as leukotriene B4, have proinflammatory effects, whereas n-3 fatty acids, such as EPA and docosahexaenoic acid (DHA; C22: 6n-3), antagonize AA cascade and show vasodilating, antiplatelet, and antithrombotic actions leading to prevention of atherosclerosis.<sup>
<xref ref-type="bibr" rid="bibr18-0003319712437031">18</xref>
<xref ref-type="bibr" rid="bibr19-0003319712437031"/>–<xref ref-type="bibr" rid="bibr20-0003319712437031">20</xref>
</sup> Both EPA and DHA have been shown to reduce cardiovascular mortality possibly mediated by improving the plasma lipid profile, endothelial function, and attenuating inflammatory or oxidative stress.<sup>
<xref ref-type="bibr" rid="bibr20-0003319712437031">20</xref>
</sup> Moreover, n-3 fatty acid intake has been shown to improve hemorheology such as blood and plasma viscosity,<sup>
<xref ref-type="bibr" rid="bibr21-0003319712437031">21</xref>,<xref ref-type="bibr" rid="bibr22-0003319712437031">22</xref>
</sup> platelet function,<sup>
<xref ref-type="bibr" rid="bibr21-0003319712437031">21</xref>,<xref ref-type="bibr" rid="bibr23-0003319712437031">23</xref>
</sup> and erythrocyte deformability.<sup>
<xref ref-type="bibr" rid="bibr21-0003319712437031">21</xref>,<xref ref-type="bibr" rid="bibr24-0003319712437031">24</xref>
</sup> These favorable biochemical, hematological, and hemorheologic effects of n-3 fatty acid exert synergistic protective action against CAD and PAD. It is reported that EPA-AA relates to the severity of CAD,<sup>
<xref ref-type="bibr" rid="bibr25-0003319712437031">25</xref>,<xref ref-type="bibr" rid="bibr26-0003319712437031">26</xref>
</sup> which is partly confirmed in the present study (<xref ref-type="table" rid="table4-0003319712437031">Table 4</xref>). Platelet function is reported to be more activated in PAD patients than in CAD patients, which is probably due to diffusely injured systemic arterial bed in PAD.<sup>
<xref ref-type="bibr" rid="bibr27-0003319712437031">27</xref>
</sup> Activated platelets lead to their aggregation that is sensitive to EPA.<sup>
<xref ref-type="bibr" rid="bibr22-0003319712437031">22</xref>
</sup> Platelet aggregation is deeply involved in atherothrombotic progression by multiple pathways mediated by thromboxane A2, adenosine diphosphate, and platelet-derived growth factor.<sup>
<xref ref-type="bibr" rid="bibr28-0003319712437031">28</xref>
</sup> These indicate that EPA-AA improvement may exert protective action against both PAD and CAD.</p>
<p>This single-center study has limitations due to small samples analyses and cross-sectional design. Therefore, this study does not guarantee the predictive value of EPA-AA ratio for future development of PAD in atherosclerotic patients. Incidence of smoking was equivalent between the 2 groups in this study (<xref ref-type="table" rid="table1-0003319712437031">Table 1</xref>). However, dietary intake of polyunsaturated fatty acids is well known to prevent atherosclerotic disease.<sup>
<xref ref-type="bibr" rid="bibr2-0003319712437031">2</xref>,<xref ref-type="bibr" rid="bibr3-0003319712437031">3</xref>
</sup> Antioxidative vitamin supplementation also has potential impact on the prevention and suppression of PAD.<sup>
<xref ref-type="bibr" rid="bibr29-0003319712437031">29</xref>
</sup> Therefore, nutritional background should have been matched more strictly.</p>
<p>In conclusion, the present study has indicated that plasma EPA-AA ratio and ABI are 2 factors independently associated with PAD at least in Japanese atherosclerotic patients. Because of the linear regression between EPA-AA and ABI, reduced plasma EPA-AA may underlie PAD. However, it is unclear in this study whether reduced plasma EPA-AA ratio as a newly recognized lipid biomarker predicts future development of PAD. Therefore, prospective studies are required to resolve this issue.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank the clinical staff in Kyushu University Hospital, Fukuoka, Japan, for their enthusiastic cooperation.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319712437031">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319712437031">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319712437031">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Criqui</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Langer</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Fronek</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Mortality over a period of 10 years in patients with peripheral arterial disease</article-title>. <source>N Engl J Med</source>. <year>1992</year>;<volume>326</volume>(<issue>6</issue>):<fpage>381</fpage>–<lpage>386</lpage>.</citation>
</ref>
<ref id="bibr2-0003319712437031">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavie</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Milani</surname>
<given-names>RV</given-names>
</name>
<name>
<surname>Mehra</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Ventura</surname>
<given-names>HO</given-names>
</name>
</person-group>. <article-title>Omega-3 polyunsaturated fatty acids and cardiovascular diseases</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>54</volume>(<issue>7</issue>):<fpage>585</fpage>–<lpage>594</lpage>.</citation>
</ref>
<ref id="bibr3-0003319712437031">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weitz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weintraub</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schwartzbard</surname>
<given-names>AZ</given-names>
</name>
</person-group>. <article-title>Fish oil for the treatment of cardiovascular disease</article-title>. <source>Cardiol Rev</source>. <year>2010</year>;<volume>18</volume>(<issue>5</issue>):<fpage>258</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr4-0003319712437031">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yokoyama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Origasa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Matsuzaki</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>369</volume>(<issue>9567</issue>):<fpage>1090</fpage>–<lpage>1098</lpage>.</citation>
</ref>
<ref id="bibr5-0003319712437031">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanaka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial</article-title>. <source>Stroke</source>. <year>2008</year>;<volume>39</volume>(<issue>7</issue>):<fpage>2052</fpage>–<lpage>2058</lpage>.</citation>
</ref>
<ref id="bibr6-0003319712437031">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishikawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease: subanalysis of the JELIS trial</article-title>. <source>Circ J</source>. <year>2010</year>;<volume>74</volume>(<issue>7</issue>):<fpage>1451</fpage>–<lpage>1457</lpage>.</citation>
</ref>
<ref id="bibr7-0003319712437031">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ecker</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>The opposing effects of n-3 and n-6 fatty acids</article-title>. <source>Prog Lipid Res</source>. <year>2008</year>;<volume>47</volume>(<issue>2</issue>):<fpage>147</fpage>–<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr8-0003319712437031">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leng</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Horrobin</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Fowkes</surname>
<given-names>FG</given-names>
</name>
<etal/>
</person-group>. <article-title>Plasma essential fatty acids, cigarette smoking, and dietary antioxidants in peripheral arterial disease. a population-based case-control study</article-title>. <source>ArteriosclerThromb</source>. <year>1994</year>;<volume>14</volume>(<issue>3</issue>):<fpage>471</fpage>–<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr9-0003319712437031">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johansson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Behre</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Bergström</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Ankle-brachial index should be measured in both the posterior and the anterior tibial arteries in studies of peripheral arterial disease</article-title>. <source>Angiology</source>. <year>2010</year>;<volume>61</volume>(<issue>8</issue>):<fpage>780</fpage>–<lpage>783</lpage>.</citation>
</ref>
<ref id="bibr10-0003319712437031">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Burgos-Lunar</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Salinero-Fort</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Cárdenas-Valladolid</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Validation of diabetes mellitus and hypertension diagnosis in computerized medical records in primary health care</article-title>. <source>BMC Med Res Methodol</source>. <year>2011</year>;<volume>11</volume>:<fpage>146</fpage>.</citation>
</ref>
<ref id="bibr11-0003319712437031">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohta</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tsuchihashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Onaka</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Clustering of cardiovascular risk factors and blood pressure control status in hypertensive patients</article-title>. <source>Intern Med</source>. <year>2010</year>;<volume>49</volume>(<issue>15</issue>):<fpage>1483</fpage>–<lpage>1487</lpage>.</citation>
</ref>
<ref id="bibr12-0003319712437031">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dachun</surname>
<given-names>Xu</given-names>
</name>
<name>
<surname>Jue</surname>
<given-names>Li</given-names>
</name>
<name>
<surname>Liling</surname>
<given-names>Zou</given-names>
</name>
<etal/>
</person-group>. <article-title>Sensitivity and specificity of the ankle-brachial index to diagnose peripheral artery disease: a structured review</article-title>. <source>Vasc Med</source>. <year>2010</year>;<volume>15</volume>(<issue>5</issue>):<fpage>361</fpage>–<lpage>369</lpage>.</citation>
</ref>
<ref id="bibr13-0003319712437031">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leng</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Fowkes</surname>
<given-names>FGR</given-names>
</name>
<name>
<surname>Horrobin</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Essential fatty acids and cardiovascular disease: the Edinburgh artery study</article-title>. <source>Vasc Med</source>. <year>1999</year>;<volume>4</volume>(<issue>4</issue>):<fpage>219</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr14-0003319712437031">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dewailly</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Blanchet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gingras</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lemieux</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Holub</surname>
<given-names>BJ</given-names>
</name>
</person-group>. <article-title>Fish consumption and blood lipids in three ethnic groups of Quebec (Canada)</article-title>. <source>Lipids</source>. <year>2003</year>;<volume>38</volume>(<issue>4</issue>):<fpage>359</fpage>–<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr15-0003319712437031">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Horiuchi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Higuchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Asano</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Lower eicosapentaenoic acid and higher arachidonic acid levels in sera of young adults in the Netherlands than in Japan</article-title>. <source>Environ Health Prev Med</source>. <year>2000</year>;<volume>5</volume>(<issue>2</issue>):<fpage>60</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr16-0003319712437031">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaur</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cameron-Smith</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sinclair</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Docosapentaenoic acid (22:5n-3): a review of its biological effects</article-title>. <source>Prog Lipid Res</source>. <year>2011</year>;<volume>50</volume>(<issue>1</issue>):<fpage>28</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr17-0003319712437031">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Potier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Abi Khalil</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mohammedi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Roussel</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Use and utility of ankle brachial index in patients with diabetes</article-title>. <source>Eur J Vasc Endovasc Surg</source>. <year>2011</year>;<volume>41</volume>(<issue>1</issue>):<fpage>110</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr18-0003319712437031">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cerbone</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Cirillo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Persistent impairment of platelet aggregation following cessation of a short-course dietary supplementation of moderate amounts of n-3 fatty acid ethylesters</article-title>. <source>Thromb Haemost</source>. <year>1999</year>;<volume>82</volume>(<issue>1</issue>):<fpage>128</fpage>–<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr19-0003319712437031">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Assaad</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Poston</surname>
<given-names>WC</given-names>
</name>
</person-group>. <article-title>Tissue omega-6/omega-3 fatty acid ratio and risk for coronary artery disease</article-title>. <source>Am J Cardiol</source>. <year>2006</year>;<volume>98</volume>(<issue>4A</issue>):<fpage>19i</fpage>–<lpage>26i</lpage>.</citation>
</ref>
<ref id="bibr20-0003319712437031">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simopoulos</surname>
<given-names>AP</given-names>
</name>
</person-group>. <article-title>The importance of omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases</article-title>. <source>Exp Biol Med</source>. <year>2008</year>;<volume>233</volume>(<issue>6</issue>):<fpage>674</fpage>–<lpage>688</lpage>.</citation>
</ref>
<ref id="bibr21-0003319712437031">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terano</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hirai</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hamazaki</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects</article-title>. <source>Atherosclerosis</source>. <year>1983</year>;<volume>46</volume>(<issue>3</issue>):<fpage>321</fpage>–<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr22-0003319712437031">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tighe</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>EJ</given-names>
</name>
</person-group>. <article-title>Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives</article-title>. <source>Atherosclerosis</source>. <year>2008</year>;<volume>197</volume>(<issue>1</issue>):<fpage>12</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr23-0003319712437031">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mann</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>O’Connell</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Baldwin</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>BJ</given-names>
</name>
</person-group>. <article-title>Effects of sea oil and tuna-fish oil on platelet parameters and plasma lipid levels in healthy subjects</article-title>. <source>Lipids</source>. <year>2010</year>;<volume>45</volume>(<issue>8</issue>):<fpage>669</fpage>–<lpage>681</lpage>.</citation>
</ref>
<ref id="bibr24-0003319712437031">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seki</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ide</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Impaired filterability of erythrocytes from patients with chronic hepatitis C and effects of eicosapentaenoic acid on the filterability</article-title>. <source>J Physiol Sci</source>. <year>2007</year>;<volume>57</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr25-0003319712437031">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kondo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Satake</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Plasma-free eicosapentaenoic acid/arachidonic acid ratio: a possible new coronary risk factor</article-title>. <source>Clin Cardiol</source>. <year>1986</year>;<volume>9</volume>(<issue>9</issue>):<fpage>413</fpage>–<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr26-0003319712437031">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kashiyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nemoto</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationship between coronary plaque vulnerability and serum n-3/n-6 polyunsaturated fatty acid ratio</article-title>. <source>Circ J</source>. <year>2011</year>;<volume>75</volume>(<issue>10</issue>):<fpage>2432</fpage>–<lpage>2438</lpage>.</citation>
</ref>
<ref id="bibr27-0003319712437031">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nambi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kimball</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Bray</surname>
<given-names>PF</given-names>
</name>
<etal/>
</person-group>. <article-title>Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD)</article-title>. <source>Platelets</source>. <year>2009</year>;<volume>20</volume>(<issue>3</issue>):<fpage>199</fpage>–<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr28-0003319712437031">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jennings</surname>
<given-names>LK</given-names>
</name>
</person-group>. <article-title>Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis</article-title>. <source>Thromb Haemost</source>. <year>2009</year>;<volume>102</volume>(<issue>2</issue>):<fpage>248</fpage>–<lpage>257</lpage>.</citation>
</ref>
<ref id="bibr29-0003319712437031">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klipstein-Grobusch</surname>
<given-names>K</given-names>
</name>
<name>
<surname>den Breeijen</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Grobbee</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Boeing</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hofman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Witteman</surname>
<given-names>JCM</given-names>
</name>
</person-group>. <article-title>Dietary antioxidants and peripheral arterial disease: the Rotterdam Study</article-title>. <source>Am J Epidemiol</source>. <year>2001</year>;<volume>154</volume>(<issue>2</issue>):<fpage>145</fpage>–<lpage>149</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>